Senores Pharma Eyes FY26 Growth Target Beat, Driven by Apnar Acquisition & Emerging Markets

• MD Swapnil Shah expects Senores Pharma to outperform its FY26 growth guidance, citing improving run rates and incremental revenues from the recently acquired Apnar Pharma facility.
• Emerging markets are projected to be a key growth driver, with revenue expected to cross ₹150 crore this year and reach ₹180–200 crore next year, supported by product commercialisation and regulatory approvals.
• Senores Pharma reported strong Q3FY26 results, with revenue up 69.4% to ₹174.56 crore, EBITDA more than doubling to ₹54 crore, and profit surging to ₹33.58 crore.
• The company's market capitalisation stands at ₹3,840.87 crore, with shares gaining nearly 64% over the past year.
• Senores Pharma is actively participating in the GLP-1 therapy market in emerging markets, having filed semaglutide (Rybelsus, Ozempic, Wegovy) in over 16 markets.

Why It Matters: Senores Pharma is poised to exceed its FY26 growth targets, fueled by strategic acquisitions and strong emerging market performance.